QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:ARDX

Ardelyx (ARDX) Stock Forecast, Price & News

$3.73
+0.10 (+2.75%)
(As of 06/6/2023 ET)
Compare
Today's Range
$3.60
$3.73
50-Day Range
$3.23
$4.95
52-Week Range
$0.49
$5.13
Volume
2.77 million shs
Average Volume
6.67 million shs
Market Capitalization
$799.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25

Ardelyx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
67.6% Upside
$6.25 Price Target
Short Interest
Healthy
7.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.32
Upright™ Environmental Score
News Sentiment
1.30mentions of Ardelyx in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$69,647 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.43) to ($0.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

167th out of 981 stocks

Pharmaceutical Preparations Industry

73rd out of 464 stocks


ARDX stock logo

About Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc. is a biopharmaceutical company. It engages in the research, development, and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Waltham, MA.

Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

ARDX Stock News Headlines

[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Ardelyx, Inc. (NASDAQ:ARDX) CEO Sells $41,453.05 in Stock
Ardelyx Insiders Land Bargain With Gains Of US$1.1m
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Ardelyx: Final Countdown Begins
Ardelyx (NASDAQ:ARDX) Downgraded by StockNews.com to Hold
Ardelyx (NASDAQ:ARDX) Upgraded to "Buy" at StockNews.com
Ardelyx (ARDX) Set to Announce Earnings on Wednesday
Ardelyx (NASDAQ:ARDX) Upgraded by StockNews.com to Buy
Ardelyx (NASDAQ:ARDX) Price Target Raised to $7.00
Ardelyx (NASDAQ:ARDX) Shares Gap Up After Analyst Upgrade
Ardelyx, Inc. (NASDAQ:ARDX) Short Interest Up 36.4% in March
See More Headlines

ARDX Price History

ARDX Company Calendar

Last Earnings
5/03/2023
Today
6/06/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARDX
Employees
86
Year Founded
2007

Price Target and Rating

Average Stock Price Forecast
$6.25
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+67.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-67,210,000.00
Net Margins
-104.52%
Pretax Margin
-104.49%

Debt

Sales & Book Value

Annual Sales
$52.16 million
Book Value
$0.50 per share

Miscellaneous

Free Float
202,667,000
Market Cap
$799.94 million
Optionable
Optionable
Beta
1.21

Social Links


Key Executives

  • Mike Raab
    President, Chief Executive Officer & Director
  • Justin A. Renz
    Chief Financial, Operations Officer & Treasurer
  • Laura A. Williams
    Chief Medical Officer
  • Elizabeth GrammerElizabeth Grammer
    Secretary, Chief Legal & Administrative Officer
  • David P. Rosenbaum
    Chief Development Officer













ARDX Stock - Frequently Asked Questions

Should I buy or sell Ardelyx stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings
or view top-rated stocks.

What is Ardelyx's stock price forecast for 2023?

3 Wall Street research analysts have issued 1-year price objectives for Ardelyx's stock. Their ARDX share price forecasts range from $3.00 to $8.00. On average, they predict the company's stock price to reach $6.25 in the next year. This suggests a possible upside of 67.6% from the stock's current price.
View analysts price targets for ARDX
or view top-rated stocks among Wall Street analysts.

How have ARDX shares performed in 2023?

Ardelyx's stock was trading at $2.85 at the start of the year. Since then, ARDX stock has increased by 30.9% and is now trading at $3.73.
View the best growth stocks for 2023 here
.

Are investors shorting Ardelyx?

Ardelyx saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 16,690,000 shares, a drop of 8.5% from the April 30th total of 18,240,000 shares. Based on an average daily trading volume, of 7,350,000 shares, the short-interest ratio is presently 2.3 days.
View Ardelyx's Short Interest
.

When is Ardelyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ARDX earnings forecast
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) posted its quarterly earnings data on Wednesday, May, 3rd. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.02. The biopharmaceutical company had revenue of $11.37 million for the quarter, compared to the consensus estimate of $10.08 million. Ardelyx had a negative net margin of 104.52% and a negative trailing twelve-month return on equity of 76.72%.

What other stocks do shareholders of Ardelyx own?
What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by many different institutional and retail investors. Top institutional investors include State Street Corp (7.09%), BlackRock Inc. (1.73%), Renaissance Technologies LLC (1.46%), Two Sigma Investments LP (1.33%), Price T Rowe Associates Inc. MD (1.19%) and Bank of America Corp DE (0.97%). Insiders that own company stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends
.

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $3.73.

How much money does Ardelyx make?

Ardelyx (NASDAQ:ARDX) has a market capitalization of $799.94 million and generates $52.16 million in revenue each year. The biopharmaceutical company earns $-67,210,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493.

This page (NASDAQ:ARDX) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -